Tags : Candidates

Teva and Alvotech Collaborate to Commercialize Five Biosimilar Candidates in

Shots: Alvotech will lead the development, registration, and supply of the biosimilars, while Teva will be exclusively commercializing the products in the US. Alvotech will receive upfront with subsequent milestone payments over the next several years The companies will share the profit from the commercialization of the biosimilars. The collaboration leverages Teva’s commercial presence and […]Read More

Evotec Signs an Agreement with Celmatix to Develop Pre-Clinical Candidates

Shots: Evotec will take care of medicinal chemistry, in vitro and in vivo pharmacology plus its development capabilities and expertise while Celmatix will utilize its novel drug target discovery based on its multi-omics Reproductive Atlas platform The focus of the agreement is to combine Celmatix database and expertise with Evotec’s footprints in therapeutic discovery with […]Read More

Janssen(J&J) Signs an Exclusive Worldwide License Agreement with MeiraGTx for

Shots: Janssen to get exclusive WW license rights to develop & commercialize certain clinical candidates in MeiraGTx’s inherited retinal disease pipeline. Janssen also has an option to license the portfolio of products for gene targeting in inherited retinal disease, will be developed in collaboration with MeiraGTx The focus of the collaboration is to develop adeno-associated […]Read More

Lilly Collaborates with AC Immune (AC) to Develop Candidates for

Shots: AC Immune to receive $80M upfront, $1760M milestones and royalties on sales and Lilly to get WW commercialization rights for AC Immune’s tau aggregation inhibitors and will invest $50M as convertible notes in AC. AC to initiate P-I study for Morphomer inhibitors and Lilly to fund the trial The focus of the agreement is to develop AC Immune’s […]Read More

Roche Collaborates with Icagen for the Development of Drug Candidates

Shots: Icagen to receive upfront, up to $274M milestones and royalties on sales from Roche and is responsible for all preclinical activities Roche to fund the program and will perform further development and commercialization activities The focus of the collaboration is to develop pre-clinical stage ion channel modulators using Icagen’s drug discovery platform, for targeting […]Read More

Evotec and Immuneering Collaborates to Develop Novel Candidates for Rare

 Shots: The collaboration is a focus of combining Evotec’s stem cell (“iPSC”) platform with Immuneering’s Artificial Intelligence drug discovery platform for development of therapies Additionally, Immuneering’s AI platform fluency will assist in analyzing public and proprietary data, for identification of novel candidates AI platform is a drug discovery based technology used to discover & develop […]Read More